Histogram
Visit number vs Epinephrine
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Baseline | 49 | 2.5 | ± 1.3 | 2.1 | 0.7 | 5.7 | - | 49 |
9-Month Followup | 42 | 7.3 | ± 5.6 | 5.3 | 1.7 | 22.7 | 1 | 43 |
18-Month Followup | 39 | 6.2 | ± 4.4 | 4.7 | 1.1 | 16.0 | 1 | 40 |
Randomized treatment arm vs Epinephrine
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 49 | 2.5 | ± 1.3 | 2.1 | 0.7 | 5.7 | - | 49 |
Laparoscopic Gastric Banding (LGB) | 28 | 2.3 | ± 1.0 | 2.1 | 0.7 | 4.9 | - | 28 |
Continuous Positive Airway Pressure (CPAP) | 21 | 2.9 | ± 1.6 | 2.6 | 1.0 | 5.7 | - | 21 |
Randomized treatment arm vs Epinephrine
9-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 42 | 7.3 | ± 5.6 | 5.3 | 1.7 | 22.7 | 1 | 43 |
Laparoscopic Gastric Banding (LGB) | 24 | 6.8 | ± 5.6 | 5.1 | 1.7 | 22.7 | 1 | 25 |
Continuous Positive Airway Pressure (CPAP) | 18 | 8.0 | ± 5.6 | 6.4 | 2.3 | 20.5 | - | 18 |
Randomized treatment arm vs Epinephrine
18-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 39 | 6.2 | ± 4.4 | 4.7 | 1.1 | 16.0 | 1 | 40 |
Laparoscopic Gastric Banding (LGB) | 24 | 6.0 | ± 4.6 | 4.4 | 1.1 | 16.0 | - | 24 |
Continuous Positive Airway Pressure (CPAP) | 15 | 6.4 | ± 4.2 | 5.9 | 1.5 | 15.1 | 1 | 16 |
Age of the participant vs Epinephrine
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 49 | 2.5 | ± 1.3 | 2.1 | 0.7 | 5.7 | - | 49 |
27.0 to 45.0 years | 13 | 3.0 | ± 1.6 | 2.7 | 1.0 | 5.7 | - | 13 |
46.0 to 50.0 years | 12 | 2.7 | ± 1.0 | 2.6 | 1.4 | 5.1 | - | 12 |
51.0 to 56.0 years | 12 | 2.3 | ± 1.1 | 1.9 | 1.2 | 4.9 | - | 12 |
57.0 to 65.0 years | 12 | 2.1 | ± 1.2 | 1.8 | 0.7 | 4.3 | - | 12 |
Age of the participant vs Epinephrine
9-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 42 | 7.3 | ± 5.6 | 5.3 | 1.7 | 22.7 | 1 | 43 |
28.0 to 47.0 years | 11 | 7.1 | ± 5.5 | 5.2 | 2.3 | 20.5 | - | 11 |
47.0 to 52.0 years | 11 | 7.7 | ± 5.9 | 6.1 | 2.2 | 18.9 | - | 11 |
52.0 to 58.0 years | 11 | 6.3 | ± 5.8 | 5.1 | 1.7 | 22.7 | - | 11 |
58.0 to 65.0 years | 9 | 8.3 | ± 5.9 | 6.3 | 2.4 | 20.7 | 1 | 10 |
Age of the participant vs Epinephrine
18-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 39 | 6.2 | ± 4.4 | 4.7 | 1.1 | 16.0 | 1 | 40 |
29.0 to 46.0 years | 10 | 6.4 | ± 4.4 | 5.3 | 1.5 | 15.1 | - | 10 |
47.0 to 52.0 years | 9 | 6.7 | ± 4.5 | 7.3 | 2.0 | 15.7 | 1 | 10 |
53.0 to 58.0 years | 10 | 3.8 | ± 2.3 | 3.1 | 1.1 | 8.4 | - | 10 |
58.0 to 65.0 years | 10 | 7.8 | ± 5.3 | 6.1 | 1.4 | 16.0 | - | 10 |
Gender of the participant vs Epinephrine
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 49 | 2.5 | ± 1.3 | 2.1 | 0.7 | 5.7 | - | 49 |
Male | 28 | 2.7 | ± 1.3 | 2.2 | 1.0 | 5.7 | - | 28 |
Female | 21 | 2.3 | ± 1.2 | 2.0 | 0.7 | 5.1 | - | 21 |
Gender of the participant vs Epinephrine
9-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 42 | 7.3 | ± 5.6 | 5.3 | 1.7 | 22.7 | 1 | 43 |
Male | 25 | 8.2 | ± 5.6 | 6.5 | 2.2 | 22.7 | - | 25 |
Female | 17 | 5.9 | ± 5.4 | 4.3 | 1.7 | 20.7 | 1 | 18 |
Gender of the participant vs Epinephrine
18-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 39 | 6.2 | ± 4.4 | 4.7 | 1.1 | 16.0 | 1 | 40 |
Male | 25 | 7.3 | ± 4.7 | 6.4 | 1.5 | 16.0 | - | 25 |
Female | 14 | 4.2 | ± 3.1 | 3.7 | 1.1 | 12.3 | 1 | 15 |
Race of the participant vs Epinephrine
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 46 | 2.6 | ± 1.3 | 2.2 | 0.7 | 5.7 | - | 46 |
white | 35 | 2.4 | ± 1.3 | 2.0 | 0.9 | 5.7 | - | 35 |
american indian or alaska native | - | - | - | - | - | - | - | - |
black or african american | 9 | 2.7 | ± 1.1 | 2.7 | 0.7 | 4.0 | - | 9 |
asian | 2 | 4.7 | ± 0.5 | 4.7 | 4.3 | 5.1 | - | 2 |
native hawaiian or other pacific islander | - | - | - | - | - | - | - | - |
other | - | - | - | - | - | - | - | - |
multiple | - | - | - | - | - | - | - | - |
Race of the participant vs Epinephrine
9-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 39 | 7.4 | ± 5.8 | 5.2 | 1.7 | 22.7 | 1 | 40 |
white | 30 | 7.4 | ± 6.1 | 5.1 | 1.7 | 22.7 | 1 | 31 |
american indian or alaska native | - | - | - | - | - | - | - | - |
black or african american | 8 | 7.0 | ± 4.8 | 6.0 | 2.4 | 16.6 | - | 8 |
asian | 1 | 10.6 | - | 10.6 | 10.6 | 10.6 | - | 1 |
native hawaiian or other pacific islander | - | - | - | - | - | - | - | - |
other | - | - | - | - | - | - | - | - |
multiple | - | - | - | - | - | - | - | - |
Race of the participant vs Epinephrine
18-Month Followup
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 36 | 6.3 | ± 4.5 | 4.7 | 1.4 | 16.0 | 1 | 37 |
white | 28 | 5.8 | ± 4.2 | 4.3 | 1.4 | 15.7 | 1 | 29 |
american indian or alaska native | - | - | - | - | - | - | - | - |
black or african american | 7 | 7.0 | ± 4.6 | 5.2 | 2.6 | 16.0 | - | 7 |
asian | 1 | 15.1 | - | 15.1 | 15.1 | 15.1 | - | 1 |
native hawaiian or other pacific islander | - | - | - | - | - | - | - | - |
other | - | - | - | - | - | - | - | - |
multiple | - | - | - | - | - | - | - | - |